Transforming HIV Care: Precision Nanomedicine for Long-Acting Therapy
Prof. Upal Roy
Associate Professor in Health & Biomedical Sciences. University of Texas Rio Grande Valley (UTRGV), USA.
Online via ZOOM
About
Transforming HIV care requires innovative strategies beyond daily antiretroviral therapy. Precision nanomedicine enables long-acting drug delivery systems that improve bioavailability, adherence, and control over pharmacokinetics. By engineering nanoparticles for targeted delivery to immune cells and viral reservoirs, this approach reduces systemic toxicity and resistance. Integrating molecular targeting with advanced biomaterials could revolutionize treatment paradigms and promote durable HIV remission.
Bio
Dr. Upal Roy, Associate Professor at the University of Texas Rio Grande Valley, holds a Ph.D. in Microbiology from Goa University. He trained in antiviral drug resistance and therapeutics at leading U.S. institutions. He has over 20 years of teaching experience, leading NIH and NASA-funded research on HIV cure strategies, neurodegeneration, and astronaut health. His work focuses on nanocarrier-based drug delivery targeting HIV reservoirs in the brain and gut and biomarker discovery in Alzheimer’s disease. Author of 47 papers, 4 book chapters and 4 patents, he also founded the biotech startup Arasus Technology and co-led the establishment of research infrastructure for minority health and cancer disparities.
Hosted by María José Alonso. Nanomedicine and Drug Delivery group, CiMUS.
Certificates of attendance will be provided upon request at cimus.xestion [at] usc.es (cimus[dot]xestion[at]usc[dot]es). Please do not forget to enter your full name and surname when registering online for the lecture.